Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60f67cf07e3fdc9c7d98b1c36039ec12 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2015-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b40569c7c79680bf9ecee2955a2f936 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_725dede99f9f426e5cd54f3716872140 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ff19b92f2facd2be08cbd575759806d |
publicationDate |
2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10696744-B2 |
titleOfInvention |
Means and methods for treating DLBCL |
abstract |
The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11434291-B2 |
priorityDate |
2010-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |